New Cream May Reverse Skin Aging Markers

Rubedo Life Sciences has announced preliminary data from early human trials of its experimental skin cream, RLS-1496. The cream demonstrated a reduction in molecular markers associated with aging and inflammation.

In a trial involving 11 patients with atopic dermatitis, four weeks of treatment resulted in an average decrease of 2.1 years in epigenetic skin age. This age estimate is based on age-related DNA changes. CEO Dr. Frederick Beddingfield noted these "significant" findings warrant further investigation, highlighting the drug's potential to address cellular aging.

The treatment targets senescent cells, which are aged or damaged cells that can promote inflammation. RLS-1496 aims to block the GPX4 protein, potentially clearing damaged cells while preserving healthier ones. The company also reported a 10% increase in skin-supporting collagen and reduced inflammation markers.

In a separate study on 22 patients with actinic keratosis, RLS-1496 achieved a 49% average reduction in rough, precancerous skin patches after 28 days. The cream showed minimal irritation and low drug detection in blood, suggesting a favorable safety profile.

Rubedo Life Sciences is also initiating trials for pattern hair loss. Beddingfield anticipates potential FDA approval in three to four years, contingent upon larger clinical trials. The company plans longer treatment durations in upcoming studies.